Possible Interaction: Silymarin and Doxorubicin Hydrochloride

“CONCLUSION IC50 of both do orubicin an d sil ymarin al one and in combination inhibited telomerase activity.”

“IC50 combinations of doxorubicin and silymarin caused 70% (p<0.05) reduction.”

“Telomerase activity of the cells incubated with IC50 of doxorubicin and silymarin decreased to 72% (p<0.05).”

“After 24 and 48 h, DNA damage in response to combined applications of doxorubicin and silymarin was indifferent from silymarin- and doxorubicin-induced damage respectively.”

“Both 24 and 48 h of silymarin and doxorubicin –silymarin combination caused significant increases in the rate of apoptotic cells.”

“The aim of this study was to investigate genotoxic and cytotoxic effects of doxorubicin, silymarin, or in combination on HepG2 cells for 24 and 48 h. Both doxorubicin and silymarin caused dose-dependent inhibition of cell proliferation.”

“ Silymarin has a synergistic effect on the therapeutic potential of doxorubicin.”

“Use of silymarin in combination with doxorubicin can be more effective on the therapeutic potential of doxorubicin and decreases its dose-limiting side effects.”

“Higher silymarin concentrations were additive with doxorubicin and paclitaxel in both cell lines.”

“According to physiological, pharmacological, microscopic and biochemical results, we confirmed that at the examined dose, silymarin exhibits a protective influence on the heart and liver tissue against toxicity induced by doxorubicin.”

“In animals treated with SMN , tissue Bcl-xL expression exceeded control values after Dox treatment.”

“Significantly, SMN exposure reduced Dox hepatotoxicity and associated apoptotic and necrotic cell death.”

“The effects of SMN on Dox were broad, including the ability to modulate changes in both Bcl-xL and p53 expression.”

“… SMN (i) reduced, … of Dox which are typically associated with hydroxyl radical production, (ii) performed as an antioxidant limiting oxidative stress, (iii) protected the integrity of the … and necrotic cell death while increasing antiapoptotic Bcl-xL protein levels and minimizing the leakage of proapoptotic cytochrome c from liver mitochondria.”

“RESULTS The … si ymarin an … orubicin in combination causes statistically significant increase of verapamil dose necessary to produce first change (2.21 : 0.62, p < 0.01); continuous reaction (2.….05) and toxic effect (3.38 : 1.87, p < 0.05) in comparison to the groups treated with silymarin or doxorubicin alone.”

“The application of silymarin prevents an increase of creatine kinase activity induced with doxorubicin (279 : 616; p < 0.0l).”

“ Silymarin and flavonolignans displayed a dose‐dependent cytoprotection against doxorubicin (100 µm, incubation 8 h).”